CD8A and neoplasm: Notably, significant difference in the maximum 89Zr-DFO-CD8a tumor-to-heart ratio between responding and non-responding groups was not observed, highlighting the necessity of understanding the relationship between specific quantitative parameters and the patient population suitable for immunotherapy.